ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.

doi:10.1186/s12943-025-02288-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.

Molecular cancer - 13 Mar 2025

Bandi Dhana Sekhar Reddy, Nagaraju Ganji Purnachandra, Sarvesh Sujith, Carstens Julienne L, Foote Jeremy B, Graff Emily C, Fang Yu-Hua D, Keeton Adam B, Chen Xi, Valiyaveettil Jacob, Berry Kristy L, Bae Sejong, Akce Mehmet, Gorman Greg, Yoon Karina J, Manne Upender, Boyd Michael R, Buchsbaum Donald J, Azmi Asfar S, Maxuitenko Yulia Y, Piazza Gary A, El-Rayes Bassel F

Abstract excerpt

BACKGROUND: Oncogenic KRAS mutations occur in nearly, 90% of patients with pancreatic ductal adenocarcinoma (PDAC). Targeting KRAS has been complicated by mutational heterogeneity and rapid resistance. We developed a novel pan-RAS inhibitor, ADT-1004 (an oral prodrug of ADT-007) and evaluated antitumor activity in murine and human PDAC models. METHODOLOGY: Murine PDAC cells with KRASG12D mutation (KPC-luc or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Cell Line, Tumor

Share to Cell Proliferation

Share to Disease Models, Animal

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40082968
DOI: 10.1186/s12943-025-02288-9
PMCID: PMC11905721

Genes

KRAS
CD4
MIA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.PMID 40082968Read ↗

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.Semantic proximity Read ↗

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Semantic proximity Read ↗

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read ↗

ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts.Semantic proximity Read ↗

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.